• BMS-777607: Advanced Strategies for MET Inhibition in hiPSC

  2026-07-15

  Explore how BMS-777607, a potent c-Met inhibitor, enables next-generation hiPSC-derived platelet production by precisely targeting MET signaling. This article delivers a uniquely integrative analysis, bridging kinase inhibition with scalable thrombopoiesis innovations.

• AI-10-49: CBFβ-SMMHC Inhibitor for Advanced Leukemia Researc

  2026-07-15

  AI-10-49 enables precise targeting of CBFβ-SMMHC in acute myeloid leukemia, restoring RUNX1 function and unveiling new therapeutic axes. Its high specificity and robust support for both cellular and in vivo workflows make it a transformative tool for dissecting leukemogenic mechanisms.

• HyperScript™ Reverse Transcriptase: Decoding RNA Complexity

  2026-07-14

  Explore how HyperScript™ Reverse Transcriptase advances cDNA synthesis for qPCR, empowering robust analysis of RNA secondary structures in adipogenesis and metabolic disease studies. Discover protocol nuances and translational insights not covered elsewhere.

• Arrb2 in Hepatocytes Mitigates Hepatic IRI via M2 Polarizati

  2026-07-14

  This study uncovers how hepatocyte-specific Arrb2 expression drives M2 macrophage polarization through upregulation of 6-ketoLCA, thereby attenuating hepatic ischemia–reperfusion injury (IRI). The work elucidates a novel metabolic-immunologic axis, offering new mechanistic insight for liver transplantation and IRI research.

• Silk Fibroin–Ce6 Nanofiber Films: Antibacterial Wound Healin

  2026-07-13

  This study introduces an aligned silk fibroin film functionalized with Chlorin e6 (Ce6), achieving rapid photodynamic antibacterial activity against S. aureus under near-infrared light. The approach not only eliminates biofilm-forming bacteria but also modulates immune responses to enhance wound healing, highlighting a new direction for infection-resistant biomaterials.

• Reserpine (SKU N1867): Protocol Guidance for Laboratory Use

  2026-07-13

  Reserpine is a high-purity reference standard used in neurotransmitter depletion research, antihypertensive mechanism studies, and neuropharmacology workflows. It is not intended for diagnostic, therapeutic, or clinical use and requires strict adherence to solubility and storage protocols to maintain experimental reliability.

• Lisinopril dihydrate: Precision ACE Inhibitor for Research

  2026-07-12

  Lisinopril dihydrate is a well-characterized, long-acting ACE inhibitor with validated specificity and high purity. Its molecular and pharmacological properties make it a foundational tool in hypertension, heart failure, and renal disease research. APExBIO supplies this compound under SKU B3290, ensuring reproducible results in preclinical applications.

• Intra- and Extracellular Dicloxacillin Activity Against S. a

  2026-07-10

  This study rigorously dissects the intra- and extracellular antibacterial efficacy of dicloxacillin against Staphylococcus aureus using both in vitro macrophage and in vivo mouse peritonitis models. By correlating pharmacokinetic/pharmacodynamic indices with observed bacterial reductions, the paper clarifies predictors of antibiotic effectiveness and informs the design of future antibacterial research models.

• Asunaprevir (BMS-650032): Applied HCV Protease Inhibition Wo

  2026-07-09

  Asunaprevir (BMS-650032) empowers hepatitis C research with nanomolar potency and broad genotype coverage, optimizing workflows from cell-based RNA inhibition to advanced mechanistic studies. This article details practical protocol enhancements, comparative advantages, and troubleshooting insights that maximize experimental success with this APExBIO benchmark compound.

• Aprotinin: Applied Workflows for Fibrinolysis Inhibition Res

  2026-07-09

  Aprotinin (Bovine Pancreatic Trypsin Inhibitor) is a cornerstone for precise serine protease inhibition in cardiovascular and inflammation research, enabling reproducible workflows and perioperative blood loss reduction. Discover how the latest protocol innovations and troubleshooting strategies maximize its impact across molecular and translational studies.

• Hoechst 33342: Strategic Nuclear Staining for Translational

  2026-07-08

  This thought-leadership article explores the mechanistic underpinnings and translational value of Hoechst 33342, a bis-benzimidazole fluorescent dye, within advanced biomedical workflows. Bridging rigorous biological rationale, contemporary validation, and the evolving needs of translational researchers, we provide actionable guidance for optimizing nuclear staining, cell cycle analysis, and apoptosis assays. The discussion is anchored by current literature and highlights APExBIO's Hoechst 33342 as a superior choice for precision and reproducibility, while also critically evaluating the competitive landscape and outlining future implications for clinical translation.

• Driving Translational mRNA Therapeutics: Mechanistic Insight

  2026-07-08

  Explore the mechanistic underpinnings and translational strategy for high-yield mRNA synthesis in neuroinflammation research, contextualized by recent breakthroughs in mRNA nanoparticle therapy for stroke. This article delivers evidence-backed workflow guidance and a critical outlook, highlighting the HyperScribe™ T7 High Yield RNA Synthesis Kit’s role in accelerating experimental and therapeutic pipelines.

• Efficient GRO-seq Profiling of Nascent RNAs in Bread Wheat

  2026-07-07

  Chen et al. present an optimized GRO-seq protocol for bread wheat that integrates ribosomal RNA depletion after nuclear isolation, dramatically increasing the yield of valid nascent RNA reads and reducing sequencing costs. This methodological advance facilitates high-resolution enhancer transcription profiling in large, complex plant genomes and can be adapted for other organisms.

• Lyso-Tracker Red DND-99: Precision Lysosome Labeling in Live

  2026-07-07

  Lyso-Tracker Red DND-99 delivers robust, high-specificity lysosome labeling for live cell imaging, enabling researchers to visualize and quantify intracellular acidic compartments with exceptional clarity. Its superior selectivity and compatibility with advanced workflows make it the probe of choice for translational research, from nanoparticle vaccine studies to disease modeling.

• Dual Terminal Oxidase Inhibition: Advancing Bactericidal TB

  2026-07-06

  This study reveals that pretomanid, a bicyclic nitroimidazole derivative, exerts potent bactericidal activity against Mycobacterium tuberculosis by simultaneously inhibiting both cytochrome bcc:aa3 and bd oxidase respiratory branches. These findings establish a mechanistic foundation for rational, synergistic drug regimens that could improve efficacy and limit resistance in tuberculosis treatment.

15428 records 1/1029 page Next 12345 下5页 Last page